Multiple Myeloma

patient care perspectives

by S. Vincent Rajkumar, MD

The management of multiple myeloma is evolving with the emergence of new agents and new approaches to treatment. The paradigm is shifting in severa......READ MORE

patient care perspectives

by Kenneth C. Anderson, MD

Since the manufacturing of chimeric antigen receptor (CAR) T-cell therapy takes time, bridging therapy is often delivered to ensure that the diseas......READ MORE

patient care perspectives

by Kenneth C. Anderson, MD

Over the last 2 decades, the outcomes for patients with multiple myeloma have dramatically improved. Immunomodulatory therapies are key constituent......READ MORE

patient care perspectives

by Sagar Lonial, MD, FACP

In both transplant and nontransplant populations, a careful balance between disease control, side effects, and quality of life must be maintained. ......READ MORE

patient care perspectives

by S. Vincent Rajkumar, MD

Lenalidomide-based triplet therapy is standard in the treatment of multiple myeloma. An all-oral triplet, with ixazomib instead of bortezomib, may ......READ MORE